Who are Metformin plus Yasmin's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/metformin-plus-yasmin.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Metformin plus Yasmin — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Metformin plus Yasmin (Metformin plus Yasmin) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Combination therapy: biguanide antidiabetic agent + oral contraceptive. Area: Endocrinology / Contraception.

phase 3 Combination therapy: biguanide antidiabetic agent + oral contraceptive Metformin: AMP-activated protein kinase (AMPK) pathway; Yasmin: progesterone receptor and estrogen receptor Endocrinology / Contraception Small molecule Live · refreshed every 30 min

Target snapshot

Metformin plus Yasmin (Metformin plus Yasmin) — Catholic University of the Sacred Heart. This combination pairs metformin, which reduces hepatic glucose production and improves insulin sensitivity, with Yasmin (drospirenone/ethinyl estradiol), a hormonal contraceptive, to address both glycemic control and contraceptive needs in women with diabetes or prediabetes.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Metformin plus Yasmin TARGET	Metformin plus Yasmin	Catholic University of the Sacred Heart	phase 3	Combination therapy: biguanide antidiabetic agent + oral contraceptive	Metformin: AMP-activated protein kinase (AMPK) pathway; Yasmin: progesterone receptor and estrogen receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Combination therapy: biguanide antidiabetic agent + oral contraceptive class)

Catholic University of the Sacred Heart · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Metformin plus Yasmin — Competitive Intelligence Brief. https://druglandscape.com/ci/metformin-plus-yasmin. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing